However, the results from preclinical models may not fully recapitulate human CRC biology, highlighting the need for further validation of the findings in clinical settings to confirm the efficacy and safety of PEITC targeting SF3A3 in CRC treatment. This evidence concerns the gene SF3A3 and colorectal carcinoma.